# Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

> **NCT03428646** · — · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 858 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT03428646
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-06
- **Primary completion:** 2027-03-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 858 (ACTUAL)
- **Last updated:** 2025-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03428646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03428646, "Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03428646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*